cabozantinib (Cabometyx)

following a full submission assessed under the end of life process:

cabozantinib (Cabometyx®) is accepted for use within NHS Scotland.

Indication under review: For the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

Cabozantinib, compared with a mammalian target of rapamycin (mTOR) inhibitor, significantly increased progression-free survival in patients with advanced or metastatic RCC who had received at least one previous regimen of VEGF receptor tyrosine kinase inhibitor.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of cabozantinib. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.